Verrica Pharmaceuticals Inc. (VRCA) company profile
Close on Nov 17, 2026Market cap $53.94MP/E –Yield –
About Verrica Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Verrica Pharmaceuticals is a clinical-stage and commercial therapeutics company focused on developing and commercializing clinician-administered medications for dermatologic diseases and skin cancers. Its primary commercial product is YCANTH, an FDA-approved topical formulation of cantharidin delivered via a single-use precision applicator for treating molluscum contagiosum. The company's development pipeline includes advancing YCANTH for the treatment of common warts, as well as developing VP-315, an investigational injectable peptide therapy for dermatological oncology conditions such as basal cell carcinoma. Its offerings primarily target pediatric dermatologists, general dermatologists, pediatricians, and other primary care health care providers.
The company operates primarily in the United States, where it employs a specialized sales organization of approximately 40 field sales representatives and contractors, and reaches approximately 250 million covered lives through insurance coverage determinations. Internationally, the company licenses commercial and development rights in Japan to Torii Pharmaceutical Co., Ltd. The provided text does not state the location of the company's headquarters.
Summary of the business section of Verrica Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Verrica Pharmaceuticals Inc.
- Headquarters
- West Chester, PA
- Address
- 44 West Gay Street, Suite 400
- Phone
- (484) 453-3300
- Website
- verrica.com
- Employees
- 76, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, Philadelphia, PA
Stock & identifiers
- Ticker
- VRCA
- Exchange
- Nasdaq
- IPO date
- Jun 15, 2018
- Shares outstanding
- 17M, Jul 31, 2026
- Public float
- $27.30M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-10 reverse, Jul 25, 2025
- SEC CIK
- 1660334
- CUSIP
- 92511W207
- ISIN
- US92511W2070
- FIGI
- BBG00L03BYB7
- Share class FIGI
- BBG00L03BZ24
- LEI
- 5493002L68H6THU5GW50
- EIN
- 46-3137900
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jayson Rieger | CEO and President, Director | 207,838 |
| Ted White | PRESIDENT AND CEO, Director | 278,789 |
| John J. Kirby | Interim CFO | 23,962 |
| Noah L. Rosenberg | CMO | 8,587 |
| David Zawitz | Chief Operating Officer | 27,000 |
| Christopher G. Hayes | CHIEF LEGAL OFFICER | 176,458 |
| Joe Bonaccorso | CHIEF COMMERCIAL OFFICER | 187,738 |
| Terry Kohler | CHIEF FINANCIAL OFFICER | 125,000 |
| Gary Goldenberg | Chief Medical Officer | 120,110 |
| Diem Nguyen | Director | 100 |
| Gavin Corcoran | Director | 20 |
| Lawrence Eichenfield | Director | – |
| Mark A. Prygocki Sr | Director | – |
| Charles Frantzreb | Director | – |
| Paul B. Manning | Director | 7,395,748 |
| John A. Stalfort III | Director | 1,873,800 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Jayson Rieger | $741.40K | $437.10K | $905.73K | $30 | – |
| FY2025 Ted White | $0 | $0 | $905.73K | $30 | – |
| FY2024 Jayson Rieger | $1.24M | $1.06M | $1.19M | $25 | – |
| FY2024 Ted White | $2.59M | -$467.92K | $1.19M | $25 | – |
| FY2023 Jayson Rieger | $0 | $0 | $2.33M | $266 | – |
| FY2023 Ted White | $3.50M | $4.64M | $2.33M | $266 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|---|
| Jayson Rieger President and Chief Executive Officer | $300.00K | – | – | $350.24K | $74.38K | $16.79K | $741.40K | -40% |
| John J. Kirby Interim Chief Financial Officer | $480.00K | $10.00K | $82.10K | – | $42.50K | – | $614.60K | +436% |
| Noah Rosenberg Chief Medical Officer | $173.86K | $25.00K | – | $139.05K | – | $9.68K | $347.59K | – |
| Christopher G. Hayes Former Chief Legal Officer | $155.33K | – | – | $100.35K | $10.00K | $481.90K | $747.58K | -27% |
| Gary Goldenberg Former Chief Medical Officer | $79.06K | – | – | $48.01K | – | $236.06K | $363.13K | -63% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jun 15, 2018
- Offer price
- $15.00
- Securities offered
- 5,000,000
- Gross proceeds
- $75.00M
- Exchange
- Nasdaq
- First trading day
- Jun 15, 2018
- First-day close
- $17.50+16.7%
- Lock-up ends (est.)
- Dec 12, 2018
“Per Share Total Public offering price $15.00 $75,000,000 Underwriting discount(1) $1.05 $5,250,000 Proceeds, before expenses, to us $13.95 $69,750,000 (1) We refer you to “Underwriting” beginning on page 151 for additional information regarding underwriting compensation.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 76 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 30, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jan 30, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Oct 8, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Nov 20, 2019 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jun 15, 2018 | IPO | Initial public offering priced (424B4 prospectus) |
| Jun 13, 2018 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?